ECSP11011558A - Nuevos compuestos químicos. - Google Patents

Nuevos compuestos químicos.

Info

Publication number
ECSP11011558A
ECSP11011558A EC2011011558A ECSP11011558A ECSP11011558A EC SP11011558 A ECSP11011558 A EC SP11011558A EC 2011011558 A EC2011011558 A EC 2011011558A EC SP11011558 A ECSP11011558 A EC SP11011558A EC SP11011558 A ECSP11011558 A EC SP11011558A
Authority
EC
Ecuador
Prior art keywords
chemical compounds
new chemical
compounds
medications
abnormal
Prior art date
Application number
EC2011011558A
Other languages
English (en)
Inventor
Heinz Stadtmueller
Ioannis Sapountzis
Daniel Kuhn
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP11011558A publication Critical patent/ECSP11011558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención comprende compuestos de la fórmula general (1)en dondeA, B, R1 a R5, Rx m, n y p tal como se definen en la reivindicación 1, que son apropiados para el tratamiento de enfermedades que están caracterizadas por una proliferación celular excesiva o anormal, preparaciones farmacéuticas que contienen tales compuestos, así como su uso como medicamentos.
EC2011011558A 2009-05-29 2011-12-27 Nuevos compuestos químicos. ECSP11011558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09161496 2009-05-29
EP10161628 2010-04-30

Publications (1)

Publication Number Publication Date
ECSP11011558A true ECSP11011558A (es) 2012-01-31

Family

ID=42289495

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011558A ECSP11011558A (es) 2009-05-29 2011-12-27 Nuevos compuestos químicos.

Country Status (22)

Country Link
US (1) US8410126B2 (es)
EP (1) EP2435411B1 (es)
JP (1) JP5756799B2 (es)
KR (1) KR20120135010A (es)
CN (1) CN102448943A (es)
AP (1) AP2011005978A0 (es)
AR (1) AR076620A1 (es)
AU (1) AU2010251943A1 (es)
BR (1) BRPI1014994A2 (es)
CA (1) CA2763700A1 (es)
CL (1) CL2011003022A1 (es)
CO (1) CO6470899A2 (es)
EA (1) EA201101674A1 (es)
EC (1) ECSP11011558A (es)
IL (1) IL216084A0 (es)
MA (1) MA33302B1 (es)
MX (1) MX2011012643A (es)
PE (1) PE20120370A1 (es)
SG (1) SG176599A1 (es)
TW (1) TW201107308A (es)
UY (1) UY32673A (es)
WO (1) WO2010136559A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293494A1 (en) * 2006-06-15 2007-12-20 Djung Jane F 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
JP5937111B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2018005356A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
WO2019190259A1 (ko) * 2018-03-30 2019-10-03 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
WO2022208454A1 (en) * 2021-04-02 2022-10-06 Bridge Biotherapeutics, Inc. N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260081B2 (en) * 2000-05-22 2005-07-28 Leo Pharma A/S Benzophenones as inhibitors of il-1beta and tnf-alpha
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003032997A1 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2004002964A1 (ja) * 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. ジアミノピリミジンカルボキサミド誘導体
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ES2338545T3 (es) * 2002-12-20 2010-05-10 Pfizer Products Inc. Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
JP4099212B2 (ja) * 2004-05-14 2008-06-11 ファイザー・プロダクツ・インク 異常な細胞増殖を処置するためのピリミジン誘導体
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US8623887B2 (en) 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
ATE497496T1 (de) * 2006-10-19 2011-02-15 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
US8138339B2 (en) * 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
KR101773313B1 (ko) * 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드

Also Published As

Publication number Publication date
KR20120135010A (ko) 2012-12-12
AR076620A1 (es) 2011-06-22
SG176599A1 (en) 2012-01-30
MX2011012643A (es) 2011-12-14
CN102448943A (zh) 2012-05-09
EA201101674A1 (ru) 2012-06-29
JP2012528121A (ja) 2012-11-12
EP2435411B1 (en) 2014-10-29
AU2010251943A1 (en) 2011-12-01
EP2435411A1 (en) 2012-04-04
MA33302B1 (fr) 2012-05-02
US20110130401A1 (en) 2011-06-02
AP2011005978A0 (en) 2011-12-31
US8410126B2 (en) 2013-04-02
CO6470899A2 (es) 2012-06-29
JP5756799B2 (ja) 2015-07-29
BRPI1014994A2 (pt) 2016-05-03
TW201107308A (en) 2011-03-01
CL2011003022A1 (es) 2012-07-13
UY32673A (es) 2010-12-31
WO2010136559A1 (en) 2010-12-02
CA2763700A1 (en) 2010-12-02
IL216084A0 (en) 2012-01-31
PE20120370A1 (es) 2012-05-09

Similar Documents

Publication Publication Date Title
ECSP11011558A (es) Nuevos compuestos químicos.
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
UY33199A (es) 5-alquinil-pirimidinas.
CR20150326A (es) Inhibidores de autotaxina
ECSP12011830A (es) Nuevos compuestos.
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX2011005934A (es) Compuestos organicos.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CL2012001971A1 (es) Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras.
ECSP099823A (es) Nuevos compuestos químicos
PE20150966A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
UY32009A (es) 5-alquinil-pirimidinas
BR112012029647A2 (pt) novos derivados de pirimidinas
UY33349A (es) Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos
ECSP11010816A (es) Nuevos Compuestos
CR20150171A (es) Benzamidas
CO6290768A2 (es) Tiazolil-dihidro-indazoles
CO6460762A2 (es) 5-alquinil-piridinas
ECSP12012110A (es) 5-alquinil-pirimidinas